The Washington Post
NEW YORK -- The Food and Drug Administration on Thursday approved the first prostate cancer chemotherapy drug found to extend the survival of men who are no longer being helped by other treatments.
The drug is called Jevtana and it is made by Sanofi-Aventis of France. The FDA approved Jevtana to treat prostate cancer that does not respond to hormone-deprivation treatments or to docetaxel, the cancer drug most commonly used to fight prostate tumors. Earlier this year, a study showed Jevtana prolonged survival for those patients by 10 weeks... read more